3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Breast Neoplasms
14
Neoplasm Metastasis
9
Stomach Neoplasms
5
Endometrial Neoplasms
4
Pancreatic Neoplasms
3
Ovarian Neoplasms
3
Adenocarcinoma
3
Salivary Gland Neoplasms
2
Prostatic Neoplasms
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Brain Neoplasms
2
Advanced Breast Cancer
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Unresectable Locally Recurrent Breast Cancer
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Osteosarcoma
1
Neoplasms
1
Neoplasm, Residual
1
Mouth Neoplasms
1
Interventions
Temozolomide
9
Specimen Handling
6
Radiotherapy
6
Magnetic Resonance Spectroscopy
6
Radiation
5
trametinib
2
dabrafenib
2
Radiotherapy, Intensity-Modulated
2
Bevacizumab
2
vorasidenib
1
vocimagene amiretrorepvec
1
veliparib
1
trastuzumab deruxtecan
1
ribociclib
1
Vorinostat
1
Spinal Puncture
1
Protons
1
Proton Therapy
1
Pluvicto
1
Nivolumab
1
Magnetic Resonance Imaging
1
Leukapheresis
1
Irinotecan
1
Ipilimumab
1
Flucytosine
1
Everolimus
1
DNA
1
Carmustine
1
Carboplatin
1
CTLA-4 Antigen
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Astrocytoma
×
trastuzumab deruxtecan
×
30 days
×
Clear all
NCT05417594
2026-06-02
CERTIS1
AstraZeneca
Phase 1/2
Recruiting
695 enrolled